跳至主要内容
临床试验/NCT06058468
NCT06058468尚未招募不适用

Cardioneuroablation of Right Anterior Ganglionated Plexus vs Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation and Enhanced Vagal Tone

St. Joseph's Centre, Poland0 个研究点目标入组 160 人开始时间: 2024年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
160
主要终点
AF recurrence

研究概览

简要总结

The goal of this study is to compare effectiveness of cardioneuroablation of right anterior ganglionated plexus and pulmonary vein isolation in patients with enhanced vagal tone expressed as deceleration capacity >7.5ms.

详细描述

Patients included into the study will be randomized to a group undergoing cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP) or pulmonary vein isolation (PVI).

In CNA group the location of RAGP will be determined anatomically below the superior vena cava ostium near the superior-septal aspect of the right atrium. Radiofrequency (RF) applications will be delivered and will be continued until heart rate (HR) acceleration >30% is achieved or if the RF time exceeds 120s.

In the PVI group point-by-point RF isolation of all pulmonary veins will be performed.

Clinical follow-up (FU) will consist of multiple ambulatory visits combined with standard ECG readings and a 7-day Holter recording. During FU visits, a detailed history of any palpitations, episodes of atrial fibrillation (AF), and hospitalizations for cardiac arrhythmias will be collected.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Paroxysmal atrial fibrillation documented in ECG or Holter monitoring
  • Deceleration capacity >7.5ms
  • Life expectancy more than 1 year
  • Age ≥18 years

排除标准

  • Permanent AF lasting more than one year or persistent AF lasting more than 7 days
  • AF secondary to electrolyte imbalance, thyroid disease, alcohol abuse, or other non-heart related causes
  • Anteroposterior dimension of the left atrium in the echocardiography ≥43mm
  • Clinically significant arrhythmias other than AF
  • Significant valvular disease
  • Valve prosthesis
  • Heart failure III or IV Class in New York Heart Association Classification
  • Previous ablation of atrial fibrillation or atrial flutter
  • History of a patent foramen ovale/atrial septal defect closure
  • History of left atrial appendage closure
  • Atrial myxoma
  • Presence of a cardiac pacemaker, defibrillator or cardiac resynchronization therapy device
  • History of pericarditis
  • Congenital heart disease
  • History of bleeding or coagulation disorders
  • Contraindications to oral anticoagulation
  • Contraindications to computed tomography or magnetic resonance imaging
  • Pregnancy or breast-feeding
  • History of transplantation
  • Severe lung disease
  • Chronic renal failure defined as estimated glomerular filtration rate (eGFR) <30 mL/min/m2
  • Significant infection
  • Life expectancy less than one year
  • Mental disorders
  • Lack of informed consent to participate in the trial

结局指标

主要结局

AF recurrence

时间窗: 1 year

AF episode lasting 30 seconds or more, documented on 12-lead ECG, event or Holter monitoring

次要结局

未报告次要终点

研究者

发起方
St. Joseph's Centre, Poland
申办方类型
Other
责任方
Principal Investigator
主要研究者

Piotr Futyma

Professor

St. Joseph's Centre, Poland

相似试验